

Angiotensin receptor blockers reduce noreflow post-PCI

April 24 2012



(HealthDay) -- For patients with acute myocardial infarction (AMI), pretreatment with angiotensin receptor blockers (ARBs) is linked with reduced incidence of the no-reflow phenomenon after percutaneous coronary intervention (PCI), according to a study published online April 10 in *Cardiovascular Therapeutics*.

To investigate the role of early ARB treatment in the development of noreflow after infarction, Tau Hu, from Xijing Hospital in Xi'an, China, and colleagues followed 276 patients with AMI who underwent successful PCI. No-reflow was evaluated by the Thrombolysis in <u>Myocardial Infarction</u> (TIMI) frame count method using angiographic images collected after PCI and stenting, with a TIMI flow grade

Citation: Angiotensin receptor blockers reduce no-reflow post-PCI (2012, April 24) retrieved 21



November 2023 from

https://medicalxpress.com/news/2012-04-angiotensin-receptor-blockers-no-reflow-post-pci.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.